Your Messages Inbox
Your Article Summary
See Latest ArticlesOnyx Pharmaceuticals Files Complaint Against Bayer Corporation
Onyx Pharmaceuticals, 05/18/09
Onyx Pharmaceuticals, Inc. announced that it has filed a complaint in the United States District Court for the Northern District of California asserting its rights to a Phase 2 anti-cancer compound discovered during joint research between Onyx and Bayer. In its complaint, Onyx seeks a declaration that fluoro-sorafenib is a jointly-owned collaboration compound under the Bayer/Onyx collaboration agreement, together with other remedies. The defendants in the complaint are Bayer Corporation and Bayer A.G. Onyx affirmed that it continues to collaborate with Bayer in the development and commercialization of Nexavar.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09
Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09
Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
Bristol Myers-Squibb Company, 12/07/09
Article Search
Sponsor